These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32748555)

  • 1. Generation of FX
    Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B
    Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
    Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
    Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.
    Roy G; Martin T; Barnes A; Wang J; Jimenez RB; Rice M; Li L; Feng H; Zhang S; Chaerkady R; Wu H; Marelli M; Hatton D; Zhu J; Bowen MA
    MAbs; 2018 Apr; 10(3):416-430. PubMed ID: 29400603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC.
    Imai-Nishiya H; Mori K; Inoue M; Wakitani M; Iida S; Shitara K; Satoh M
    BMC Biotechnol; 2007 Nov; 7():84. PubMed ID: 18047682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
    Kanda Y; Imai-Nishiya H; Kuni-Kamochi R; Mori K; Inoue M; Kitajima-Miyama K; Okazaki A; Iida S; Shitara K; Satoh M
    J Biotechnol; 2007 Jun; 130(3):300-10. PubMed ID: 17559959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering nucleotide sugar synthesis pathways for independent and simultaneous modulation of N-glycan galactosylation and fucosylation in CHO cells.
    Prabhu A; Shanmugam D; Gadgil M
    Metab Eng; 2022 Nov; 74():61-71. PubMed ID: 36152932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cloning and expression of GDP-D-mannose-4,6-dehydratase, a key enzyme for fucose metabolism defective in Lec13 cells.
    Ohyama C; Smith PL; Angata K; Fukuda MN; Lowe JB; Fukuda M
    J Biol Chem; 1998 Jun; 273(23):14582-7. PubMed ID: 9603974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of afucosylated antibodies in CHO cells by coexpression of an anti-FUT8 intrabody.
    Joubert S; Guimond J; Perret S; Malenfant F; Elahi SM; Marcil A; Parat M; Gilbert M; Lenferink AEG; Baardsnes J; Durocher Y
    Biotechnol Bioeng; 2022 Aug; 119(8):2206-2220. PubMed ID: 35509261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
    Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of fucosylation inhibitors for production of afucosylated antibody.
    Xu P; Ou YC; Smith M; Paulson J; Schmidt MA; Kandari L; Parsons R; Khetan A
    Biotechnol Prog; 2024; 40(3):e3438. PubMed ID: 38415431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Yamane-Ohnuki N; Kinoshita S; Inoue-Urakubo M; Kusunoki M; Iida S; Nakano R; Wakitani M; Niwa R; Sakurada M; Uchida K; Shitara K; Satoh M
    Biotechnol Bioeng; 2004 Sep; 87(5):614-22. PubMed ID: 15352059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma.
    Wang Y; Huang D; Chen KY; Cui M; Wang W; Huang X; Awadellah A; Li Q; Friedman A; Xin WW; Di Martino L; Cominelli F; Miron A; Chan R; Fox JG; Xu Y; Shen X; Kalady MF; Markowitz S; Maillard I; Lowe JB; Xin W; Zhou L
    Gastroenterology; 2017 Jan; 152(1):193-205.e10. PubMed ID: 27639802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase with GDP-mannose-4,6-dehydratase stabilizes the enzyme activity for formation of GDP-fucose from GDP-mannose.
    Nakayama K; Maeda Y; Jigami Y
    Glycobiology; 2003 Oct; 13(10):673-80. PubMed ID: 12881408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facile Modulation of Antibody Fucosylation with Small Molecule Fucostatin Inhibitors and Cocrystal Structure with GDP-Mannose 4,6-Dehydratase.
    Allen JG; Mujacic M; Frohn MJ; Pickrell AJ; Kodama P; Bagal D; San Miguel T; Sickmier EA; Osgood S; Swietlow A; Li V; Jordan JB; Kim KW; Rousseau AC; Kim YJ; Caille S; Achmatowicz M; Thiel O; Fotsch CH; Reddy P; McCarter JD
    ACS Chem Biol; 2016 Oct; 11(10):2734-2743. PubMed ID: 27434622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
    von Horsten HH; Ogorek C; Blanchard V; Demmler C; Giese C; Winkler K; Kaup M; Berger M; Jordan I; Sandig V
    Glycobiology; 2010 Dec; 20(12):1607-18. PubMed ID: 20639190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell lines expressing mutant FX proteins to generate proteins with reduced rate of fucosylation: WO2010/141478.
    Taupin P
    Expert Opin Ther Pat; 2011 Jul; 21(7):1143-6. PubMed ID: 21554153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
    Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
    MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.